Insufficient targeting specificity represents a core bottleneck: although glutaminase inhibitors (e.g., CB-839) can reduce ammonia accumulation in CD8+ T cells, their concurrent suppression of glutamine metabolism in tumor cells may exacerbate nutrient competition within the immune microenvironment, thereby impairing T-cell function (127, 202). The gene discussed is CD8A; the disease is neoplasm.